Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Change in Cash: 2016-2024

Historic Change in Cash for Mereo BioPharma Group (MREO) over the last 9 years, with Dec 2024 value amounting to $12.4 million.

  • Mereo BioPharma Group's Change in Cash rose 13.61% to -$7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.7 million, marking a year-over-year decrease of 292.82%. This contributed to the annual value of $12.4 million for FY2024, which is 215.05% up from last year.
  • As of FY2024, Mereo BioPharma Group's Change in Cash stood at $12.4 million, which was up 215.05% from -$10.8 million recorded in FY2023.
  • In the past 5 years, Mereo BioPharma Group's Change in Cash ranged from a high of $97.0 million in FY2021 and a low of -$46.6 million during FY2022.
  • In the last 3 years, Mereo BioPharma Group's Change in Cash had a median value of -$10.8 million in 2023 and averaged -$15.0 million.
  • In the last 5 years, Mereo BioPharma Group's Change in Cash soared by 857.70% in 2021 and then tumbled by 148.05% in 2022.
  • Yearly analysis of 5 years shows Mereo BioPharma Group's Change in Cash stood at $10.1 million in 2020, then spiked by 857.70% to $97.0 million in 2021, then tumbled by 148.05% to -$46.6 million in 2022, then spiked by 76.92% to -$10.8 million in 2023, then spiked by 215.05% to $12.4 million in 2024.